Top 10 Pharmacovigilance Deficiencies Identified by the TGA (and How to Avoid Them)
Pharmacovigilance (PV) is a regulatory obligation, but in practice it is often treated as a secondary function until something goes wrong. The Therapeutic Goods Administration (TGA) continues to identify recurring deficiencies across sponsors of all sizes, particularly within listed medicines and complementary products. These findings are rarely due to a lack of intent; more often, they reflect gaps in systems, oversight, and practical implementation.
Below is a consolidated view of the most common PV deficiencies observed in the Australian context, along with pragmatic guidance on how to address them.
1. Absence of a Clearly Defined PV System
Deficiency:
Sponsors are unable to demonstrate a structured pharmacovigilance system. Documentation is fragmented, outdated, or entirely absent.
How to avoid it:
Establish a documented PV framework that clearly outlines responsibilities, processes, and oversight. Even small sponsors should maintain a simplified but coherent system, including procedures, templates, and governance structure. The system should be proportionate to the product portfolio but sufficiently robust to withstand inspection.
2. Lack of a Pharmacovigilance System Master File (PSMF)
Deficiency:
No PSMF is maintained, or the document exists but is incomplete, outdated, or inconsistent with actual practices.
How to avoid it:
Maintain a living PSMF that accurately reflects your PV system at all times. It should describe key elements such as organisational structure, reporting pathways, vendors, and quality systems. Regular review cycles and version control are essential.
3. Inadequate Adverse Event (AE) Collection Processes
Deficiency:
Sponsors rely on passive or informal channels for AE collection, with no systematic approach to capturing safety information from all relevant sources.
How to avoid it:
Define clear intake channels, including medical information, customer service, social media, and distributors. Train all relevant staff to recognise and forward potential adverse events. Ensure that even minimal information is captured and assessed.
4. Delayed or Missed Reporting to the TGA
Deficiency:
Serious adverse events are not reported within required timelines, or reporting obligations are misunderstood.
How to avoid it:
Implement clear timelines aligned with TGA requirements and embed them into operational workflows. Use tracking tools or case management systems to monitor deadlines. Regular reconciliation exercises can help ensure completeness.
5. Poor Quality Case Documentation
Deficiency:
Case records are incomplete, lack essential details, or are not adequately assessed for seriousness and causality.
How to avoid it:
Adopt standardised case processing templates and ensure consistency in documentation. Train staff or vendors on minimum data requirements and assessment criteria. Periodic quality checks are critical to maintaining standards.
6. Insufficient Oversight of PV Vendors
Deficiency:
Outsourced PV activities are not adequately supervised. Sponsors are unable to demonstrate control over third-party providers.
How to avoid it:
Vendor oversight should include due diligence, formal agreements, defined responsibilities, and ongoing performance monitoring. Regular audits and clear communication channels are essential. Outsourcing does not transfer regulatory accountability.
7. Lack of Training and Awareness
Deficiency:
Staff are unaware of PV obligations or do not understand their role in adverse event reporting.
How to avoid it:
Implement a structured training program covering PV fundamentals, reporting obligations, and internal processes. Training should extend beyond PV personnel to include any function that may receive safety information. Maintain training records as evidence of compliance.
8. Inadequate Signal Detection and Risk Management
Deficiency:
Sponsors are unable to demonstrate how safety signals are identified, assessed, or managed.
How to avoid it:
For many sponsors, signal detection does not require complex systems but does require a defined approach. Periodic review of adverse event data, trend analysis, and documented decision-making processes are expected. Escalation pathways should be clearly defined.
9. Poor Documentation of Procedures (or Lack Thereof)
Deficiency:
Standard Operating Procedures (SOPs) are missing, outdated, or not reflective of actual practice.
How to avoid it:
Develop concise, practical SOPs that align with your operations. Avoid overcomplication, but ensure all critical PV activities are covered. Regular review and alignment with real-world practice are key.
10. Limited Quality Assurance (QA) Oversight
Deficiency:
There is little to no independent review of PV activities, and deviations are not systematically identified or addressed.
How to avoid it:
Introduce basic QA mechanisms such as internal audits, periodic reviews, and deviation management. Even a lean QA function can significantly improve compliance by identifying gaps early and ensuring continuous improvement.
Final Thoughts
Most PV deficiencies identified by the TGA are not the result of complex regulatory misunderstandings. They stem from gaps in execution, oversight, and consistency. Importantly, these issues are preventable with a structured, proportionate approach to pharmacovigilance.
For sponsors, the goal should not be to build an overly complex system, but rather one that is clear, defensible, and consistently applied. A well-implemented PV system not only meets regulatory expectations but also protects product integrity and brand reputation in an increasingly scrutinised environment.
